{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002861","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.280141+00:00","generated_at":"2026-06-02T01:39:19.370376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptose posts Q1 net loss of $9.6M; advances TUS+VEN+HMA triplet to clinical site activation","bullets":["Net loss of $9.6M ($0.73/share) vs $13.7M ($2.22) a year ago; cash $9.3M expected to fund through August 2024.","Tuspetinib triplet (TUS+VEN+HMA) protocol for ND AML submitted to FDA; clinical sites being activated; initial data expected Q4 2024.","Stockholders' equity positive $137k as of March 31, but Nasdaq equity deficiency notice remains; compliance plan due May 17, 2024.","EHA 2024 poster accepted for TUS monotherapy and TUS+VEN doublet data in R/R AML; preclinical data showing TUS activity against VEN-resistant AML.","Nasdaq compliance regained regarding Hanmi warrant issue; second deficiency notice for equity minimum still open."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002861","json":"https://secwatch.observer/filing/0001171843-24-002861.json","markdown":"https://secwatch.observer/filing/0001171843-24-002861.md","text":"https://secwatch.observer/filing/0001171843-24-002861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/0001171843-24-002861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/f8k_051424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:39:19.370376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb8e665f27578f62f39820384f913962d9a6d632","claim":"Aptose Biosciences Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Aptose Biosciences Inc. (\"Aptose\" or the \"Company\") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/0001171843-24-002861-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}